# US 2014/0271660 A1 · Monoclonal antibodies against antithrombin beta

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271660 A1
- Document ID: US20140271660A1
- Status: Published application
- Kind: A1
- Application number: 14/214,267
- Filed: 2014-03-14
- Published: 2014-09-18
- Earliest claimed: 2013-03-14
- Assignees: Bayer HealthCare LLC
- Applicants: Bayer Healthcare LLC
- Inventors: YE JIN; JOHN E. MURPHY; TERRY HERMISTON; TIMOTHY MYLES; FRANK DITTMER; MICHAEL STRERATH; UWE GRITZAN
- Web page: https://patentgrep.com/patent/US20140271660A1

## CPC

- C07K 16/36: against blood coagulation factors
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C07K 16/18: against material from animals or humans
- C07K 16/38: against protease inhibitors of peptide structure
- C07K 2317/21: from primates, e.g. man
- C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin β complexed with heparin and/or heparin-like structure (ATβH). These ATβH binding proteins can block the anti-coagulant activity of ATβ to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.

## Claims

### Claim 1

A monoclonal antibody capable of binding the antithrombin (β) heparin complex (ATβH), wherein the heavy chain of said antibody comprises: a CDR1 sequence of amino acids 31 to 35 (AYRMG) of SEQ ID NO: 2, a CDR2 sequence of amino acids 50 to 66 (RIYSSGGRTRYADSVKG) of SEQ ID NO: 2, and a CDR3 sequence of amino acids 97 to 114 (AREKASDLSGSFSEALDY) of SEQ ID NO: 2; and
wherein the light chain of said antibody comprises: a CDR1 sequence of amino acids 24 to 34 (QGDSLRSYYAS) of SEQ ID NO: 1, a CDR2 sequence of amino acids 50 to 56 (GKNNRPS) of SEQ ID NO: 1; and a CDR3 sequence of amino acids 89 to 99 (NSRDSSGNHLV) of SEQ ID NO: 1.

### Claim 2

A monoclonal antibody capable of binding ATβH, wherein the heavy chain of said antibody comprises: a CDR1 sequence of amino acids 31 to 35 (KYKMD) of SEQ ID NO: 4, a CDR2 sequence of amino acids 50 to 66 (RIGPSGGKTM YADSVKG) of SEQ ID NO: 4, and a CDR3 sequence of amino acids 97 to 114 (AREKASDLSG TYSEALDY) of SEQ ID NO: 4; and
wherein the light chain of said antibody comprises: a CDR1 sequence of amino acids 26 to 37 (RASQSVSSSYLA) of SEQ ID NO: 3, a CDR2 sequence of amino acids 53 to 59 (GASSRAT) of SEQ ID NO: 3, and a CDR3 sequence of amino acids 92 to 99 (QQYGSSRT) of SEQ ID NO: 3.

### Claim 3

A monoclonal antibody capable of binding ATβH, wherein the heavy chain of said antibody comprises: a CDR1 sequence of amino acids 31 to 35 (KYRMD) of SEQ ID NO: 6, a CDR2 sequence of amino acids 50 to 66 (RIGPSGGKTT YADSVKG) of SEQ ID NO: 6, and a CDR3 sequence of amino acids 97 to 114 (AREKTSDLSG SYSEALDY) of SEQ ID NO: 6; and
wherein the light chain of said antibody comprises: a CDR1 sequence of amino acids 26 to 36 (RASQNINRNLA) of SEQ ID NO: 5, a CDR2 sequence of amino acids 52 to 58 (TASTRAP) of SEQ ID NO: 5, and a CDR3 sequence of amino acids 91 to 99 (QQYASPPRT) of SEQ ID NO: 6.

### Claim 4

A monoclonal antibody capable of binding ATβH, wherein the heavy chain of said antibody comprises: a CDR1 sequence of amino acids 31 to 35 (RYAMY) of SEQ ID NO: 8, a CDR2 sequence of amino acids 50 to 66 (RISPSGGKTH YADSVKG) of SEQ ID NO: 8, and a CDR3 sequence of amino acids 97 to 115 (ARLSQTGYYP HYHYYGMDV) of SEQ ID NO 8; and
wherein the light chain of said antibody comprises: a CDR1 sequence of amino acids 26 to 37 (RASQRVSSSYLT) of SEQ ID NO: 7, a CDR2 sequence of amino acids 53 to 59 (GASSRAT) of SEQ ID NO: 7; and a CDR3 sequence of amino acids 92 to 101 (QQYDSTPPLT) of SEQ ID NO: 7.

### Claim 5

An isolated monoclonal antibody that binds to ATβH and inhibits anticoagulant activity, wherein said antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, and 8, and amino acid sequences having substantial homology to SEQ ID NOS: 2, 4, 6, and 8.

### Claim 6 (depends on 6)

The isolated monoclonal antibody of claim 6, further comprising a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5 and 7, and amino acid sequences having homology to SEQ ID NOS: 1, 3, 5, and 7.

### Claim 7

An isolated monoclonal antibody that binds to AtβH and inhibits anticoagulant activity, wherein said antibody further comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, and 7, and amino acid sequences having substantial homology to SEQ ID NOS: 1, 3, 5, and 7.

### Claim 8

An isolated monoclonal antibody that binds to ATβH and inhibits anticoagulant activity, wherein said antibody comprises a CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 39, 40, 41, and 42.

### Claim 9 (depends on 8)

The isolated monoclonal antibody of claim 8, further comprising: (a) a CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 31, 32, 33, and 34; (b) a CDR2 comprising an amino acid sequence selected from the group consisting of SEQ. ID NOS: 35, 36, 37, and 38; or (c) both a CDR1 comprising an amino acid sequence selected from the group consisting of SEQ. ID NOS: 31, 32, 33, and 34 and a CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 35, 36, 37, and 38.

### Claim 10

An isolated monoclonal antibody that binds to ATβH and inhibits anticoagulant activity, wherein said antibody comprises a CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 27, 28, 29, and 30.

### Claim 11 (depends on 10)

The isolated monoclonal antibody of claim 10, further comprising: (a) a CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 19, 20, 21 and 22; (b) a CDR2 comprising an amino acid sequence selected from the group consisting of SEQ. ID NOS: 23, 24, 25, and 26; or (c) both CDR1 comprising an amino acid sequence selected from the group consisting of SEQ. ID NOS: 19, 20, 21 and 22 and a CDR2 comprising and amino acid sequence selected from the group consisting of SEQ ID NOS: 23, 24, 25, and 26.

### Claim 12

An isolated monoclonal antibody that binds to the active site of ATβH.

### Claim 13

An isolated monoclonal antibody that binds to ATβH and provides anticoagulant activity, wherein the isolated monoclonal antibody exhibits minimal binding to AT and wherein said antibody is a fully human antibody.

### Claim 14 (depends on 1)

The isolated monoclonal antibody of claim 1, wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, a secretory IgA, an IgD, an IgE antibody, and an antibody fragment.

### Claim 15

An isolated monoclonal antibody that binds to human ATβH.

### Claim 16 (depends on 15)

The isolated monoclonal antibody of claim 15, wherein the antibody further binds to a nonhuman species of ATβH.

### Claim 17 (depends on 1)

The isolated monoclonal antibody of claim 1, wherein blood clotting time in the presence of the antibody is shortened.

### Claim 18 (depends on 1)

An antibody which would compete with the isolated monoclonal antibody of claim 1.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the monoclonal antibody of claim 1 and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A method for treating a genetic or acquired deficiency or a defect in coagulation comprising administering a therapeutically effective amount of a pharmaceutical composition of claim 1 to a patient.

### Claim 21 (depends on 19)

A method for treating coagulopathy comprising administering a therapeutically effective amount of a pharmaceutical composition of claim 19 to a patient.

### Claim 22 (depends on 21)

The method of claim 21, wherein the coagulopathy is hemophilia A, hemophilia B, or hemophilia C.

### Claim 23 (depends on 21)

The method of claim 21, wherein the coagulopathy is selected from the group consisting of trauma-induced coagulopathy and severe bleeding.

### Claim 24 (depends on 21)

The method of claim 21, further comprising administering a clotting factor.

### Claim 25 (depends on 24)

The method of claim 24, wherein the clotting factor is selected from the group consisting of Factor VIIa, Factor VIII, and Factor IX.

### Claim 26 (depends on 19)

A method for shortening bleeding time comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 19 to a patient.

### Claim 27

An isolated nucleic acid molecule encoding an antibody that binds to ATβH and inhibits anticoagulant activity, wherein the antibody comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, and 7.

### Claim 28

An isolated nucleic acid molecule encoding an antibody that binds to ATβH and inhibits anticoagulant activity, wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, and 8.

### Claim 29 (depends on 20)

The method of claim 20, wherein the defect in coagulation is hemophilia A, hemophilia B or hemophilia C.
